Dr Reddy's

Dr Reddy's launches new generic Ozempic brands amid Obeda supply disruption

Obeda Pro and ​Obeda Plus are made by a different manufacturer than the original Obeda injectable, supplies of which were ‌halted in July after Dr Reddy's discovered an impurity in active ingredients

Dr Reddy's gets DCGI nod for cancer drug's second indication in India

The approval allows toripalimab with cisplatin and paclitaxel as first-line treatment for unresectable advanced, recurrent or metastatic ESCC in adults

Dr Reddy's receives DCGI approval for esophageal cancer drug Zytorvi

Dr Reddy's Laboratories on Wednesday said it has received approval from the Drugs Controller General of India (DCGI) for Zytorvi (toripalimab), through which it aims to expand access to first-line immunotherapy for patients with advanced esophageal squamous cell carcinoma (ESCC) in India. The drug has been approved in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic ESCC, the pharma company said in a release. This marks Zytorvi's second approved indication in the country, expanding beyond nasopharyngeal carcinoma. ESCC accounts for approximately 80 per cent of all esophageal cancer cases in India, the company said. Zytorvi contains toripalimab, a monoclonal antibody that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, thereby supporting T-cell activity against cancer cells. The approval is supported by results from the Phase 3 JUPITER-06 trial. In the study, toripalimab in .

Dr Reddy's signs India distribution deal for Takeda's Qdenga dengue vaccine

The deal comes months after India's drug regulator approved Qdenga for use in both children and adults, making it the first dengue vaccine cleared for the country

Dr Reddy's may underperform on growth, margin worries after muted Q1

North America weakness, lower margins, uncertainty over key launches weigh on earnings outlook

GLP-1 opportunity to lift domestic business at Indian pharmaceutical firms

The expanding domestic market for semaglutide-based weight-loss drugs is expected to help cushion weaker US sales for Cipla and Dr Reddy's after the loss of Revlimid exclusivity

Dr Reddy's Foundation targets 100k soil samples ahead of rabi season

Dr Reddy's Foundation -- a family-owned trust and one of the key beneficiaries of the CSR funds of pharma major Dr Reddy's Laboratories -- is scaling up operations at its Hyderabad soil testing facility with the lab targeting between 75,000 and 1,00,000 samples ahead of the next Rabi season -- more than double what it processed in its first full year of operations. The move comes amid growing concern over depleting soil health and implementation gaps in the Centre's Soil Health Card scheme rolled out nationally in 2015. "Though the government's soil testing ecosystem exists, the scale of the problem is huge. So we decided to address this issue in our own way," said Suman Saraswathibatla, Director (Rural Livelihoods and Climate Action) at the foundation. This soil testing facility is central to the Foundation's broader soil health and regenerative agriculture programme, under which assessing soil condition is treated as the starting point for any intervention. The push for an in-hou

Dr Reddy's delays semaglutide supplies over active ingredient quality issue

Drugmaker said certain batches of semaglutide failed to meet quality specifications, prompting a delay in commercial supplies, while maintaining there is no impact on patient safety

Dr Reddy's delays semaglutide supplies over active ingredient quality issue

Drugmaker said certain batches of semaglutide failed to meet quality specifications, prompting a delay in commercial supplies, while maintaining there is no impact on patient safety

DRL gets 7 observations after USFDA inspection of Hyderabad biologics plant

USFDA completed a pre-license inspection of the Hyderabad facility and issued a Form 483 with seven observations, which the company said it will address within the stipulated timeline

Dr Reddy's launches generic oral leukaemia drug Bosutinib in US market

The company has launched a generic version of Pfizer's Bosulif for chronic myeloid leukaemia and secured 180 days of exclusivity for the 400 mg strength

Dr Reddy's unveils oral diabetes drug Obeda for type 2 patients in India

The once-daily prescription tablet for type 2 diabetes received CDSCO approval after a Phase III trial showed comparable efficacy and safety to the innovator drug

Biosimilars could surpass generics in US mkt by early 2030s: Dr Reddy's CEO

Dr Reddy's CEO Erez Israeli says semaglutide, biosimilars and oncology will drive the company's next growth phase as it expands beyond traditional generics globally

Canada approves DRL's Ozempic generic after months of regulatory logjam

DRL is the first company to receive market authorisation for a generic semaglutide injection in Canada. It is the first generic semaglutide to be approved in a G7 country

Brazil rejects Dr Reddy's, Cipla GLP-1 generics on technical grounds

Brazil's regulator Anvisa rejects DRL and Cipla's generic GLP-1 drug filings, citing unmet technical requirements on efficacy, safety and quality

Corona Remedies acquires Wokadine from DRL, enters iodine market

Acquisition of Wokadine marks Corona Remedies' entry into India's Rs 648 crore povidone iodine segment, strengthening its specialty portfolio and distribution reach

Delhi HC pauses DRL's Olymviq rollout as it sounds similar to Ozempic

Court flags phonetic similarity with Novo Nordisk's Ozempic, directs Dr Reddy's to halt expansion amid trademark dispute over diabetes drug branding

Dr Reddy's enters semaglutide market, launches diabetes generic drug

Drugmaker expects to receive regulatory approval for weightloss sema generic in a few months

Sun Pharma, Dr Reddy's, Glenmark launch generic semaglutide in India

Indian pharma majors Sun Pharma, Dr Reddy's and Glenmark on Saturday announced the launch of their generic versions of semaglutide injection used for diabetes and weight management following the molecule behind products like Ozempic and Wegovy going off patent in India. The prices of the generic versions of semaglutide injection are considerably lower than the prices of the innovator, Novo Nordisk. Sun Pharmaceutical Industries launched its semaglutide injection under the brand names Noveltreat and Sematrinity in India, in all strengths. Noveltreat is indicated for chronic weight management in adults as an adjunct to a reduced calorie diet and increased physical activity and is available in five dose strengths -- 0.25 mg/0.5 ml, 0.5 mg/0.5 ml, 1 mg/0.5 ml, 1.7 mg/0.75 ml, and 2.4 mg/0.75 ml, Sun Pharma said in a statement. Sematrinity is indicated for treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise and is available in t

Dr Reddy's likely to launch generic semaglutide Obeda in India in March

Hyderabad-based Dr Reddy's has applied to trademark the Obeda brand and logo, a government filing showed